Home » Stocks » SNDX

Syndax Pharmaceuticals, Inc. (SNDX)

Stock Price: $20.23 USD -1.07 (-5.02%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
Market Cap 954.54M
Revenue (ttm) 1.52M
Net Income (ttm) -66.74M
Shares Out 44.16M
EPS (ttm) -1.87
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $20.23
Previous Close $21.30
Change ($) -1.07
Change (%) -5.02%
Day's Open 21.03
Day's Range 19.85 - 21.30
Day's Volume 765,668
52-Week Range 6.65 - 26.44

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
PRNewsWire - 1 month ago

WALTHAM, Mass., Dec. 18, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative...

Seeking Alpha - 1 month ago

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company focused on a 2-product pipeline including SNDX-5613, a Menin inhibitor for MLLR/NPM1, and SNDX-6352, a monoclonal antibody ...

PRNewsWire - 1 month ago

WALTHAM, Mass., Dec. 9, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative ...

PRNewsWire - 1 month ago

WALTHAM, Mass., Dec. 7, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative ...

Zacks Investment Research - 1 month ago

Investors need to pay close attention to Syndax Pharmaceuticals (SNDX) stock based on the movements in the options market lately.

PRNewsWire - 1 month ago

WALTHAM, Mass., Dec. 6, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative ...

PRNewsWire - 1 month ago

WALTHAM, Mass., Nov. 30, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative...

PRNewsWire - 2 months ago

WALTHAM, Mass., Nov. 11, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative...

Seeking Alpha - 2 months ago

Syndax Pharmaceuticals, Inc. (SNDX) CEO Briggs Morrison on Q3 2020 Results - Earnings Call Transcript

Seeking Alpha - 5 months ago

Syndax Pharmaceuticals, Inc. (SNDX) CEO Briggs Morrison on Q2 2020 Results - Earnings Call Transcript

PRNewsWire - 5 months ago

WALTHAM, Mass., Aug. 6, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc.

Seeking Alpha - 7 months ago

Syndax's Latest Data Disappoints, But The True Value Lies With SNDX-5613 And SNDX-6352

Investors Business Daily - 8 months ago

Syndax Pharmaceuticals stock tumbled to a month-low Friday after the biotech's breast cancer treatment failed in a Phase 3 test. Syndax says it won't be asking for FDA approval.

PRNewsWire - 8 months ago

WALTHAM, Mass., May 21, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX) today announced receipt of the final results of E2112, the Phase 3 clinical trial conducted by ECOG-ACR...

Seeking Alpha - 8 months ago

Syndax Pharmaceuticals, Inc. (SNDX) CEO Briggs Morrison on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

Syndax (SNDX) delivered earnings and revenue surprises of -9.80% and -0.26%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

The Motley Fool - 8 months ago

Initial data from an early-stage leukemia trial is promising.

Investors Business Daily - 8 months ago

Shares of Syndax Pharmaceuticals soared to a record high Tuesday after the biotech company unveiled promising results for its early-stage blood cancer treatment in leukemia patients. The post...

Zacks Investment Research - 8 months ago

Syndax (SNDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 10 months ago

As of late, it has definitely been a great time to be an investor in Syndax Pharmaceuticals.

Seeking Alpha - 10 months ago

Syndax Pharmaceuticals, Inc. (SNDX) CEO Briggs Morrison on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 10 months ago

Syndax (SNDX) delivered earnings and revenue surprises of 4.35% and 0.00%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 11 months ago

As of late, it has definitely been a great time to be an investor Syndax Pharmaceuticals, Inc. (SNDX).

Seeking Alpha - 1 year ago

Syndax Pharmaceuticals, Inc. (SNDX) CEO Briggs Morrison on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Syndax (SNDX) delivered earnings and revenue surprises of 14.58% and -0.26%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

Syndax (SNDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

24/7 Wall Street - 1 year ago

Needless to say, the biotech world has had a difficult 2019, with the SPDR S&P Biotech ETF (NYSE: XBI) down 20% from highs posted in April.

Other stocks mentioned: APLS, MDCO
Zacks Investment Research - 1 year ago

Investors need to pay close attention to Syndax (SNDX) stock based on the movements in the options market lately.

Seeking Alpha - 1 year ago

Syndax Pharmaceuticals, Inc. (SNDX) CEO Briggs Morrison on Q2 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Syndax (SNDX) delivered earnings and revenue surprises of -6.82% and -2.82%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

Syndax (SNDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

InvestorPlace - 1 year ago

As stocks keep pushing to highs again and again, where can you find smart stocks to buy right now? Check out these 7 excellent options.

Other stocks mentioned: MS, NFLX, OGI, QURE, REAL, SFIX
Seeking Alpha - 1 year ago

Syndax Pharmaceuticals' (SNDX) CEO Briggs Morrison on Q1 2019 Results - Earnings Call Transcript

About SNDX

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. The company's lead product candidates are entinostat that is in Phase III clinical trials for the treatment of advanced hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer; and SNDX-5613 in Phase I/II clinical trial inhibitor that targets the binding interaction of Menin with mixed lineage leukemia-rearranged and acute myeloid leukemia with a mutated nucleophosmin 1. It al... [Read more...]

Industry
Biotechnology
IPO Date
Mar 3, 2016
CEO
Arlene Morris
Employees
35
Stock Exchange
NASDAQ
Ticker Symbol
SNDX
Full Company Profile

Financial Performance

In 2019, SNDX's revenue was $1.52 million, a change of 0.00% compared to the previous year's $1.52 million. Losses were -$56.05 million, -24.22% less than in 2018.

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for SNDX stock is "Strong Buy." The 12-month stock price forecast is 32.50, which is an increase of 60.65% from the latest price.

Price Target
$32.50
(60.65% upside)
Analyst Consensus: Strong Buy